RECORDATI GROUP — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications3liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
OsilodrostatOsilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and/or dysglycaemia clinically relevant and statistically significant reductions in blood pressure and glycaemia. This study aims at providing additional evidence on the safety, efficacy and appropriate dosing of osilodrostat in patients with CS, who have hypertension.	Hypertension	Phase 4	À vérifier		À vérifier
OsilodrostatOsilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and/or dysglycaemia clinically relevant and statistically significant reductions in blood pressure and glycaemia. This study aims at providing additional evidence on the safety, efficacy and appropriate dosing of osilodrostat in patients with CS, who have hypertension.	Hypertension	Phase 4	À vérifier		À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
Osilodrostat	Hypertension	Phase 4	NCT07247162	LINC CARE — Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome	NOT_YET_RECRUITING

Publications

3

Molécule	Indication / population	Titre	Journal	Date
Osilodrostat		Is Hypercortisolism Treatable? Which Patients Should Be Treated and How-A Practical Guide for Clinicians.	Diabetes, obesity & metabolism
Osilodrostat		Protracted osilodrostat-induced pan-adrenal steroidogenic suppression and adrenal size reduction in Cushing disease.	JCEM case reports
Osilodrostat		Ectopic ACTH-dependent Cushing syndrome in 3 hospitalized patients: lessons learned from management with osilodrostat.	JCEM case reports